Experts on senolytics: 'The science is mature enough to take seriously, but nowhere near ready for widespread use'
Cellular senescence has grown into one of the central themes in longevity science. But how far has the field actually come? A roundtable with leading experts lays bare both the promise and the blind spots.
Senescent cells do something paradoxical: they stop dividing, which protects against cancer, yet at the same time they secrete a cocktail of harmful substances that fuels chronic inflammation. In young, healthy tissue, the immune system clears them out quickly. As you age, that process becomes less and less effective, and the cells begin to accumulate. The idea of targeting them for elimination through senolytics, or suppressing their damaging secretions through senolytics, has given rise to an entirely new research field over the past decade.
Lifespan.io brought together a group of experts for a wide-ranging look at where things stand. The consensus: the science is robust enough to take seriously, but translating it into clinical applications is proving far more complicated than early animal models suggested. A recurring theme in the discussion is the heterogeneity of senescence itself. Not all senescent cells are alike, not all tissues respond the same way, and "senescent" is less a binary state than a spectrum of conditions.
What senolytics can and cannot do
The most extensively studied senolytics, dasatinib combined with quercetin, have now completed multiple clinical trials, including in kidney failure, idiopathic pulmonary fibrosis, and diabetic kidney disease. Results are promising in some contexts but far from consistent across the board. Experts point out that dosing and timing appear to be critical: administering the drugs too early, too late, or too frequently can undermine their therapeutic effect or worsen side effects.
Measurement is another problem. There is still no widely accepted biomarker for senescence in humans, no blood test that reliably tells you how many senescent cells are present, where they are, or whether a treatment has actually reduced their numbers. That makes trials difficult to design and results hard to interpret. Without reliable biomarkers, the question of whether a treatment is working remains largely unanswered by indirect means.
Commercial pressure on a young field
Outside academia, the market for senolytic supplements is growing fast. Quercetin and fisetin are already widely available, despite the fact that evidence for their senolytic effect in humans is thin at best. Experts are concerned about the widening gap between scientific caution and commercial claims. The risk is not only that consumers waste money on products that do not work; it is also that poorly documented use will complicate the interpretation of future trials.
The field stands at a crossroads. The fundamental biology is compelling. The translational challenges are real. And the commercial pressure to move faster than the science can justify is considerable.